Litcius/Paper detail

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

Volkan Granit, Michael Benatar, Metin Kurtoğlu, Miloš D. Miljković, Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, Adam Slansky, Tuan Vu, Christopher M. Jewell, Michael S. Singer, Murat V. Kalayoglu, James F. Howard, Tahseen Mozaffar, Volkan Granit, Michael Benatar, Tahseen Mozaffar, Nizar Chahin, James F. Howard, Adam D. Slansky, Marc H. Feinberg, Gregory Sahagian, Tuan Vu, Denise Pereira, Julie Steele, Maria Elena Paredes, Cara L. Benjamin, Krishna V. Komanduri, Ali A. Habib, Julia Kimberly Fong, Luis de la Cruz‐Merino, Diana Dimitrova, Manisha Chopra, Kelly Holley, Gabrielle DeMaria, April Tenorio, Naraly Requena, Beverly Mackanzie Brooks, Niraja Suresh, Jerrica Farias, Miloš D. Miljković, Metin Kurtoğlu, Minhtran Ngo Casi, Adam Chowdhury, Hafsa Kamboh, Charles A. Stewart, Mehmet Tosun, Yufei Shan, S. E. Daniel, Matthew T. Duvernay, Maria L. Kireeva, Emily English, Christopher M. Jewell, Michael S. Singer, Murat V. Kalayoglu, Michael S. Singer, Murat V. Kalayoglu

2023The Lancet Neurology256 citationsDOIOpen Access PDF

Topics & Concepts

Myasthenia gravisMedicineTolerabilityInternal medicineAdverse effectChimeric antigen receptorAntigenAutoantibodyImmunologyImmunotherapyGastroenterologyAntibodyCancerCAR-T cell therapy researchMyasthenia Gravis and ThymomaMonoclonal and Polyclonal Antibodies Research
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study | Litcius